Ignyta, UCSF In Clinical Trial Deal

San Diego-based oncology products developer Ignyta said late Monday that it is in a clinical trial collaboration with the University of California, San Francisco (UCSF). Ignysta said that UCSF will study its compound, entrectinib, in a proof-of-concept clinical trial in cancer patients with metastatic melanoma. Ignyta said it will contribute $1M towards funding of the clinical trial, plus per-patient fees.